Furthermore, immunological targeting of CD133 by a vaccine, ICT-121, containing autologous dendritic cells loaded with two HLA-A2 restricted epitopes of the CD133 antigen, in patient with recurrent gliomas was found both safe and well-tolerable [22]. This evidence concerns the gene PROM1 and central nervous system cancer.